These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10720512)

  • 81. AIDS foundation seeks withdrawal of approval for HIV drug combination.
    Clarke B
    Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502
    [No Abstract]   [Full Text] [Related]  

  • 82. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
    Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
    Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
    Frissen PH; de Vries J; Weigel HM; Brinkman K
    AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
    [No Abstract]   [Full Text] [Related]  

  • 84. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.
    Stuyver L; Wyseur A; Rombout A; Louwagie J; Scarcez T; Verhofstede C; Rimland D; Schinazi RF; Rossau R
    Antimicrob Agents Chemother; 1997 Feb; 41(2):284-91. PubMed ID: 9021181
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis.
    van 't Wout AB; de Jong MD; Kootstra NA; Veenstra J; Lange JM; Boucher CA; Schuitemaker H
    J Infect Dis; 1996 Oct; 174(4):845-9. PubMed ID: 8843227
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
    Johnson VA
    J Infect Dis; 1995 Mar; 171 Suppl 2():S140-9. PubMed ID: 7861019
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reverse transcriptase of HIV as a target for anti-viral drugs.
    Darby G
    Biochem Soc Trans; 1992 May; 20(2):505-8. PubMed ID: 1383062
    [No Abstract]   [Full Text] [Related]  

  • 88. Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
    Veldkamp AI; Sparidans RW; Hoetelmans RM; Beijnen JH
    J Chromatogr B Biomed Sci Appl; 1999 Dec; 736(1-2):123-8. PubMed ID: 10676991
    [TBL] [Abstract][Full Text] [Related]  

  • 89. HLA B57 and abacavir hypersensitivity.
    Flexner C
    Hopkins HIV Rep; 2002 May; 14(3):5. PubMed ID: 12206099
    [No Abstract]   [Full Text] [Related]  

  • 90. Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.
    Bonfanti P; Faggion I; La Seta Catamancio S; Violin M; Balotta C; Rusconi S
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1767. PubMed ID: 10896652
    [No Abstract]   [Full Text] [Related]  

  • 91. Targets for antiviral therapy of human immunodeficiency virus infection.
    Jeffries DJ
    J Infect; 1989 Jan; 18 Suppl 1():5-13. PubMed ID: 2464649
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Reversible zidovudine-induced pure red cell aplasia.
    Blanche P; Silberman B; Barreto L; Gombert B; Sicard D
    AIDS; 1999 Aug; 13(12):1586-7. PubMed ID: 10465087
    [No Abstract]   [Full Text] [Related]  

  • 93. Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection.
    Yarchoan R; Mitsuya H; Broder S
    Am J Med; 1989 Aug; 87(2):191-200. PubMed ID: 2474251
    [No Abstract]   [Full Text] [Related]  

  • 94. 1592 compassionate use program.
    Highleyman L
    BETA; 1997 Sep; ():3. PubMed ID: 11364697
    [TBL] [Abstract][Full Text] [Related]  

  • 95. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues.
    Wong JK; Ignacio CC; Torriani F; Havlir D; Fitch NJ; Richman DD
    J Virol; 1997 Mar; 71(3):2059-71. PubMed ID: 9032338
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Use of floxuridine to modulate the antiviral activity of zidovudine.
    Medina DJ; Tung PP; Sathya B; Strair RK
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):965-8. PubMed ID: 8827211
    [No Abstract]   [Full Text] [Related]  

  • 97. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.
    Turner D; Brenner B; Wainberg MA
    Clin Diagn Lab Immunol; 2003 Nov; 10(6):979-81. PubMed ID: 14607855
    [No Abstract]   [Full Text] [Related]  

  • 98. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults.
    McDowell JA; Chittick GE; Stevens CP; Edwards KD; Stein DS
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1686-90. PubMed ID: 10817729
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV).
    Bekker A; Decloedt EH; Slade G; Cotton MF; Rabie H; Cressey TR
    Clin Infect Dis; 2021 Jun; 72(11):2032-2034. PubMed ID: 32697327
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Abacavir Induces Arterial Thrombosis in a Murine Model.
    Collado-Diaz V; Andujar I; Sanchez-Lopez A; Orden S; Blanch-Ruiz MA; Martinez-Cuesta MA; Blas-García A; Esplugues JV; Álvarez Á
    J Infect Dis; 2018 Jun; 218(2):228-233. PubMed ID: 29346575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.